ArticleCancers2019

Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.

Ryusuke Hori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.